Other formats:
BibTeX
LaTeX
RIS
@article{1713418,
author = {Šrámková, Taťána and Šrámková, K. and Jarkovský, Jiří and Pohanka, Michal and Čermák, Aleš},
article_location = {Westchester},
article_number = {4},
doi = {http://dx.doi.org/10.26717/BJSTR.2020.26.004386},
keywords = {Erectile Dysfunction; Diabetes Type 2; Endothelial Dysfunction; Topical Alprostadil; International Index of Erectile Function; Erectile Hardness Score},
language = {eng},
issn = {2574-1241},
journal = {Biomedical Journal of Scientific & Technical Research},
title = {Examining Endothelial Dysfunction and The Effect of Topical Treatment with Prostaglandin E1 In Diabetics Suffering from Erectile Dysfunction},
url = {https://biomedres.us/fulltexts/BJSTR.MS.ID.004386.php},
volume = {26},
year = {2020}
}
TY - JOUR
ID - 1713418
AU - Šrámková, Taťána - Šrámková, K. - Jarkovský, Jiří - Pohanka, Michal - Čermák, Aleš
PY - 2020
TI - Examining Endothelial Dysfunction and The Effect of Topical Treatment with Prostaglandin E1 In Diabetics Suffering from Erectile Dysfunction
JF - Biomedical Journal of Scientific & Technical Research
VL - 26
IS - 4
SP - 20160-20166
EP - 20160-20166
PB - Biomedical Research Network
SN - 25741241
KW - Erectile Dysfunction
KW - Diabetes Type 2
KW - Endothelial Dysfunction
KW - Topical Alprostadil
KW - International Index of Erectile Function
KW - Erectile Hardness Score
UR - https://biomedres.us/fulltexts/BJSTR.MS.ID.004386.php
L2 - https://biomedres.us/fulltexts/BJSTR.MS.ID.004386.php
N2 - Aims: Erectile and endothelial dysfunctions are the most common complications of diabetes. We studied the endothelial function and response to treatment of a topical alprostadil in diabetics with erectile dysfunction. Sample and Methods: 30 patients were enrolled in the non-intervention, postregistration, prospective study with 300 (MU)g alprostadil cream. We examined vascular endothelial function using an ENDO-PAT 2000 device. We used International Index of Erectile Function (IIEF-5), Erectile Hardness Score (EHS), Global Assessment Questionnaire (GAQ) and Sexual Encounter Profile Q 2 and 3 (SEP 2, SEP 3) to assess erectile function. The primary outcome measures were the proportion of patients with an optimal treatment response at baseline and at 6 and 12 weeks after treatment and the evaluation of patients and their partner’s subjective satisfaction. Results: We diagnosed endothelial dysfunction in 15 diabetics. After 12 weeks of treatment with alprostadil 53.3% of the sample, reached normal erectile function. We found a significant increase in IIEF-5 scores with a median of 6 points (range 0–19, p<0.001) after 6 weeks compared to baseline, and of 7 points (range 0–20, p<0.001) after 12 weeks of treatment compared to baseline; a significant increase occurred both after 6 and 12 weeks of treatment (p=0.002). After both 6 and 12 weeks we found a significant increase in erection rigidity, EHS, compared to baseline (p< 0.001, p = 0.014). After 12 weeks of treatment, GAQ, improving erectile function was reached in 76.7% patients. Conclusion: We have demonstrated that topical alprostadil is efficient in diabetic men with erectile-endothelial dysfunction.
ER -
ŠRÁMKOVÁ, Taťána, K. ŠRÁMKOVÁ, Jiří JARKOVSKÝ, Michal POHANKA and Aleš ČERMÁK. Examining Endothelial Dysfunction and The Effect of Topical Treatment with Prostaglandin E1 In Diabetics Suffering from Erectile Dysfunction. \textit{Biomedical Journal of Scientific \&{} Technical Research}. Westchester: Biomedical Research Network, 2020, vol.~26, No~4, p.~20160-20166. ISSN~2574-1241. Available from: https://dx.doi.org/10.26717/BJSTR.2020.26.004386.
|
